Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

“Alnylam’s commercial and clinical achievements ... with the potential launch of vutrisiran in ATTR-CM delivering significant topline growth as reflected in our net product sales guidance ...

Reports Q4 revenue $593.17M, consensus $580.62M. “2024 was another year of impressive execution for Alnylam (ALNY), generating product revenues ...

Alnylam Pharmaceuticals Inc (ALNY) reports robust financial performance with a 33% revenue growth and outlines strategic ...

Amvuttra (vutrisiran), as well as for Givlaari (givosiran) and Oxlumo (lumasiran). In the past three months, shares of Alnylam have gained 12.5% compared with the industry’s growth of 7.7%.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and ...